Related references
Note: Only part of the references are listed.Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer
Wen Lee Tan et al.
CANCER BIOLOGY & THERAPY (2011)
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
Kyung-Hun Lee et al.
CANCER LETTERS (2010)
Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Paul Workman et al.
CANCER RESEARCH (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer
Taro Matsuzaki et al.
CANCER SCIENCE (2009)
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma
Sandrine Guillard et al.
CELL CYCLE (2009)
Gastric cancer in the era of molecularly targeted agents: current drug development strategies
Hendrik-Tobias Arkenau
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
M-A Westhoff et al.
ONCOGENE (2009)
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
Neil E. Torbett et al.
BIOCHEMICAL JOURNAL (2008)
Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy
P. H. Clingen et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells
Xinxin Bu et al.
CANCER BIOLOGY & THERAPY (2008)
Live or let die: E2F1 and PI3K pathways intersect to make life or death decisions
Brian David Dyniacht
CANCER CELL (2008)
Class IPI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
Remko Prevo et al.
CANCER RESEARCH (2008)
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma
Qi-Wen Fan et al.
CANCER RESEARCH (2007)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Human tumor mutants in the p110α subunit of PI3K
Zhenning Liu et al.
CELL CYCLE (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers
P Michl et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
GJ Peters et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
Share Paper
